Home
/
UNITED THERAPEUTICS Corp
/
Financials
/
Quarterly
UNITED THERAPEUTICS Corp — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that UNITED THERAPEUTICS Corp filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2020
Mar 31, 2020
$356.30M
Apr 29, 2020
Q3
2019
Sep 30, 2019
$401.50M
Oct 30, 2019
Q2
2019
Jun 30, 2019
$373.60M
Jul 31, 2019
Q1
2020
Mar 31, 2019
$362.60M
Apr 29, 2020
Q3
2019
Sep 30, 2018
$412.70M
Oct 30, 2019
Q2
2019
Jun 30, 2018
$444.50M
Jul 31, 2019
Q1
2019
Mar 31, 2018
$389.20M
May 1, 2019
Q3
2018
Sep 30, 2017
$445.50M
Oct 31, 2018
Q2
2018
Jun 30, 2017
$444.60M
Aug 1, 2018
Q1
2018
Mar 31, 2017
$370.50M
May 2, 2018
Q3
2017
Sep 30, 2016
$408.20M
Oct 25, 2017
Q2
2017
Jun 30, 2016
$412.60M
Jul 27, 2017
Q1
2017
Mar 31, 2016
$369.00M
Apr 26, 2017
Q3
2016
Sep 30, 2015
$386.20M
Oct 27, 2016
Q2
2016
Jun 30, 2015
$347.20M
Jul 28, 2016
Q1
2016
Mar 31, 2015
$327.50M
Apr 28, 2016
Q3
2015
Sep 30, 2014
$329.95M
Oct 27, 2015
Q2
2015
Jun 30, 2014
$322.80M
Jul 28, 2015
Q1
2015
Mar 31, 2014
$289.40M
Apr 28, 2015
Q3
2014
Sep 30, 2013
$302.23M
Oct 28, 2014
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$799.50M
Oct 29, 2025
Q2
2025
Jun 30, 2025
$798.60M
Jul 30, 2025
Q1
2025
Mar 31, 2025
$794.40M
Apr 30, 2025
Q3
2025
Sep 30, 2024
$748.90M
Oct 29, 2025
Q2
2025
Jun 30, 2024
$714.90M
Jul 30, 2025
Q1
2025
Mar 31, 2024
$677.70M
Apr 30, 2025
Q3
2024
Sep 30, 2023
$609.40M
Oct 30, 2024
Q2
2024
Jun 30, 2023
$596.50M
Jul 31, 2024
Q1
2024
Mar 31, 2023
$506.90M
May 1, 2024
Q3
2023
Sep 30, 2022
$516.00M
Nov 1, 2023
Q2
2023
Jun 30, 2022
$466.90M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$461.90M
May 3, 2023
Q3
2022
Sep 30, 2021
$444.70M
Nov 2, 2022
Q2
2022
Jun 30, 2021
$446.50M
Aug 3, 2022
Q1
2022
Mar 31, 2021
$379.10M
May 4, 2022
Q3
2021
Sep 30, 2020
$380.10M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$362.00M
Aug 4, 2021
Q1
2021
Mar 31, 2020
$356.30M
May 5, 2021
Q3
2020
Sep 30, 2019
$401.50M
Oct 28, 2020
Q2
2020
Jun 30, 2019
$373.60M
Jul 29, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$338.70M
Oct 29, 2025
Q2
2025
Jun 30, 2025
$309.50M
Jul 30, 2025
Q1
2025
Mar 31, 2025
$322.20M
Apr 30, 2025
Q3
2025
Sep 30, 2024
$309.10M
Oct 29, 2025
Q2
2025
Jun 30, 2024
$278.10M
Jul 30, 2025
Q1
2025
Mar 31, 2024
$306.60M
Apr 30, 2025
Q3
2024
Sep 30, 2023
$267.60M
Oct 30, 2024
Q2
2024
Jun 30, 2023
$259.20M
Jul 31, 2024
Q1
2024
Mar 31, 2023
$240.90M
May 1, 2024
Q3
2023
Sep 30, 2022
$239.30M
Nov 1, 2023
Q2
2023
Jun 30, 2022
$116.00M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$239.90M
May 3, 2023
Q3
2022
Sep 30, 2021
$162.70M
Nov 2, 2022
Q2
2022
Jun 30, 2021
$172.60M
Aug 3, 2022
Q1
2022
Mar 31, 2021
$28.30M
May 4, 2022
Q3
2021
Sep 30, 2020
$171.20M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$107.10M
Aug 4, 2021
Q1
2021
Mar 31, 2020
$137.70M
May 5, 2021
Q3
2020
Sep 30, 2019
$132.40M
Oct 28, 2020
Q2
2020
Jun 30, 2019
$205.10M
Jul 29, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$388.50M
Oct 29, 2025
Q2
2025
Jun 30, 2025
$364.50M
Jul 30, 2025
Q1
2025
Mar 31, 2025
$382.80M
Apr 30, 2025
Q3
2025
Sep 30, 2024
$343.10M
Oct 29, 2025
Q2
2025
Jun 30, 2024
$319.90M
Jul 30, 2025
Q1
2025
Mar 31, 2024
$356.30M
Apr 30, 2025
Q3
2024
Sep 30, 2023
$327.00M
Oct 30, 2024
Q2
2024
Jun 30, 2023
$313.40M
Jul 31, 2024
Q1
2024
Mar 31, 2023
$284.40M
May 1, 2024
Q3
2023
Sep 30, 2022
$314.30M
Nov 1, 2023
Q2
2023
Jun 30, 2022
$201.80M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$288.00M
May 3, 2023
Q3
2022
Sep 30, 2021
$228.70M
Nov 2, 2022
Q2
2022
Jun 30, 2021
$222.20M
Aug 3, 2022
Q1
2022
Mar 31, 2021
($64.80M)
May 4, 2022
Q3
2021
Sep 30, 2020
$221.10M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$140.50M
Aug 4, 2021
Q1
2021
Mar 31, 2020
$166.70M
May 5, 2021
Q3
2020
Sep 30, 2019
$183.40M
Oct 28, 2020
Q2
2020
Jun 30, 2019
$221.40M
Jul 29, 2020